Core Insights - Pelthos Therapeutics has initiated the first human clinical trial for CT2000, targeting both acute and chronic ocular pain associated with dry eye disease [1][2] - CT2000 is a NaV1.7 inhibitor, which has shown promise in pre-clinical studies for treating various pain indications [2][3] Company Overview - Pelthos Therapeutics is a biopharmaceutical company focused on innovative therapeutic products for unmet patient needs, with a portfolio that includes ZELSUVMI™, Xepi®, and Xeglyze® [5] - The company is advancing its pipeline through its subsidiary Channel Pharmaceutical Corporation, which owns the rights to CT2000 [1][5] Clinical Trial Details - The Phase 1b/2a trial will assess the safety and efficacy of CT2000 in patients with moderate to severe dry eye disease and chronic eye pain, featuring an adaptive design [2] - Results from the trial are expected by the end of 2026, following a 28-day dosing period [2] Market Potential - The global chronic ocular pain market is projected to reach $5.3 billion by 2032, indicating significant commercial potential for effective treatments [4]